Business
MedMira Reports First Quarter Results FY2026
HALIFAX, NOVA SCOTIA / ACCESS Newswire / December 30, 2025 / MedMira Inc. (MedMira) (TSXV:MIR)...
About this update from Medmira Inc.
MedMira Reports First Quarter Results FY2026HALIFAX, NOVA SCOTIA / ACCESS Newswire / December 30, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2025.Corporate updateIn Q1 FY2026, the Company received the Health Canada approval for its Reveal® TP (Syphilis) rapid test. This major milestone allows the Company to offer the fastest rapid test approved in Canada to detect the antibodies against Syphilis. The aim is to provide a highly sensitive and reliable Point-of-Care testing solution in any setting to support the fight against the increasing rates of infectious cases. This approval marks a further milestone in the Company's growing product portfolio and validates MedMira's unique RVF Technology platform.In addition, the Company commenced on its second phase of the clinical trials for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP) to support its already completed first phase for regulatory submission.Major milestonesWith the Health Canada approval received for MedMira's Reveal® TP (Syphilis) rapid test in Q1 FY2026, the Company commenced with its distribution partners to gain provincial validations and implementation into the various provincial and private buying groups. The Reveal® TP (Syphilis) rapid test complements its already HIV and TP/HIV Health Canada approved products and with it offers health care professionals the flexibility to choose the right test for their patient. MedMira is committed to expand its product offering in Canada with reliable, high quality rapid test that are truly rapid and can be utilized in any setting.During FY2025, the Company completed its first clinical trial phase in Canada for its unique Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP). This independent publication was sponsored by the University of Ottawa, the Public Health Laboratory Canada and the Microbiology Laboratory in Winnipeg with Dr. Patrick O'Byrne as the principal investigator. Subsequent to Q1 FY2026, this evaluation and its clinical data have been published by BMC infectious diseases and outlined the high sensitivity and specificity of the Multiplo® TP/nTP and the significant effectiveness of this Point-of-Care product. The overall conclusion outlined that rapid tests may enable front-line health car...